A detailed history of Sargent Bickham Lagudis LLC transactions in Exact Sciences Corp stock. As of the latest transaction made, Sargent Bickham Lagudis LLC holds 235 shares of EXAS stock, worth $12,509. This represents 0.0% of its overall portfolio holdings.

Number of Shares
235
Previous 235 -0.0%
Holding current value
$12,509
Previous $7,000 57.14%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2021

Jul 19, 2021

SELL
$93.66 - $139.27 $7,867 - $11,698
-84 Reduced 26.33%
235 $29,000
Q1 2021

May 24, 2021

SELL
$116.57 - $155.01 $130,092 - $172,991
-1,116 Reduced 77.77%
319 $42,000
Q4 2020

May 24, 2021

BUY
$99.61 - $142.12 $111,164 - $158,605
1,116 Added 349.84%
1,435 $190,000
Q4 2020

May 24, 2021

SELL
$99.61 - $142.12 $7,769 - $11,085
-78 Reduced 19.65%
319 $42,000
Q1 2020

Sep 07, 2021

BUY
$37.9 - $104.44 $11,066 - $30,496
292 Added 278.1%
397 $23,000
Q1 2019

Sep 13, 2021

BUY
$61.98 - $96.5 $6,507 - $10,132
105 New
105 $9,000

Others Institutions Holding EXAS

About EXACT SCIENCES CORP


  • Ticker EXAS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 176,960,000
  • Market Cap $9.42B
  • Description
  • Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...
More about EXAS
Track This Portfolio

Track Sargent Bickham Lagudis LLC Portfolio

Follow Sargent Bickham Lagudis LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sargent Bickham Lagudis LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sargent Bickham Lagudis LLC with notifications on news.